[1] 张露,孙伟,华建武,等.维持性血液透析患者死亡原因分析[J].临床荟萃,2014,29(12):1375-1378.
[2] 高燕,王怀坤,王子竞,等.维持性透析患者恶性肿瘤的发生情况与相关因素探讨[J].海南医学,2018,29(4):491-493.
[3] 黄洁丽,刘熹,余晨,等.维持性血液透析患者恶性肿瘤的发生情况分析[J].同济大学学报(医学版),2015,36(5):57-60.
[4] Marquardt P,Krause R,Schaller M,et al.Vitamin D status and cancer prevalence of hemodialysis patients in Germany[J].Anticancer Res,2015,35(2):1181-1187.
[5] Yoo KD,Lee JP,Lee SM,et al.Cancer in Korean patients with end-stage renal disease:A 7-year follow-up[J].PLoS One,2017,12(7):e0178649.
[6] Chien CC,Han MM,Chiu YH,et al.Epidemiology of cancer in end-stage renal disease dialysis patients:a national cohort study in Taiwan[J].J Cancer,2017,8(1):9-18.
[7] Ou CH,Yang WH.Long-term outcomes of complete urinary tract exenteration for dialysis patients with urothelial cancer[J].Int Urol Nephrol,2017,49(4):623-627.
[8] Lin MY,Kuo MC,Hung CC,et al.Association of dialysis with the risks of cancers[J].PLoS One,2015,10(4):e0122856.
[9] 张静波,杨惠标.长期透析患者获得性肾囊性病与肾癌[J].重庆医学,2001,30(1):78-80.
[10] 刘苏来,安瑞华,俞秋霞,等.血液透析并发膀胱尿路上皮癌临床特点及透析龄对其生存期的影响[J].现代泌尿外科杂志,2013,18(3):244-246,260.
[11] 赵慧萍,孟宪文,隋准,等.维持性透析患者恶性肿瘤的发生情况与相关因素探讨[J].中国血液净化,2008,7(2):71-74.
[12] 田媚. 慢性肾功能衰竭患者在血液透析期间恶性肿瘤的发病状况及其发病原因[J].实用癌症杂志,2017,32(10):1710-1712,1715.
[13] Heidland A,Bahner U,Vamvakas S.Incidence and spectrum of dialysis-associated cancer in three continents[J].Am J Kidney Dis,2000,35(2):347-351.
[14] Gallagher MP,Kelly PJ,Jardine M,et al.Long-term cancer risk of immunosuppressive regimens after kidney transplantation[J].J Am Soc Nephrol,2010,21(5):852-858.
[15] 张怡玲,尹永红,赵久阳.透析患者并发恶性肿瘤的临床分析[J].大连医科大学学报,2010,32(5):555-557,568.
[16] Lee YC,Hung SY,Wang HK,et al.Is there different risk of cancer among end-stage renal disease patients undergoing hemodialysis and peritoneal dialysis?[J].Cancer Med,2018, 7(2):485-498.
[17] Li CE,Chien CS,Chuang YC,et al.Chronic kidney disease as an important risk factor for tumor recurrences,progression and overall survival in primary non-muscle-invasive bladder cancer[J].Int Uro Nephrol,2016,48(6):993-999.
[18] Pedrazzoli P,Silvestris N,Santoro A,et al.Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN)[J].ESMO Open,2017, 2(3):e000167.
[19] Gupta A,Cosper PC.Renal cancer complicating acquired cystic kidney disease[J].J Am Soc Nephrol,1994,5(6):1407-1408.
[20] Chudek J,Herbers J,Wilhelm M,et al.The genetics of renal tumors in end-stage renal failure differs from those occurring in the general population[J].J Am Soc Nephrol,1998,9(6): 1045-1051.
[21] Kato S,Chmielewski M,Honda H,et al.Aspects of immune dysfunction in end-stage renal disease[J].Clin J Am Soc Nephrol, 2008,3(5):1526-1533.
[22] Kang CH,Yu TJ,Hsieh HH,et al.The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract[J].Cancer, 2003,98(8):1620-1626.
[23] Kobatake K,Hayashi T,Black PC,et al.Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer[J].Int J Urol,2017,24(8):594-600.
[24] Yuge K,Miyajima A,Tanaka N,et al.Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer[J].Ann Surg Oncol,2012,19(12):3987-3993.
[25] Funakoshi T,Horimatsu T,Nakamura M,et al.Chemotherapy in cancer patients undergoing haemodialysis:a nationwide study in Japan[J].ESMO Open,2018,3(2):e000301.
[26] Satoh S,Tsuchiy N,Habuchii T,et al.Renal cell and transitional cell carcinoma in a japanese population undergoing maintenance dialysis[J].J Urol,2005,174(5):1749-1753.
[27] Tseng SF,Chuang YC,Yang WC.Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma[J].Int Urol Nephrol,2011,43(4):1067-1071.
[28] Schiffmannab J,Gandagliaacd G,Larcheracd A,et al.Contemporary 90-day mortality rates after radical cystectomy in the elderly[J].Eur J Surg Oncol,2014,40(12):1738-1745. |
